Investing.com -- Central Asia Metals plc (LSE:CAML) has decided not to submit a counterproposal to Kinterra’s latest offer for New World Resources (NWR), the company announced Monday. Kinterra increased its offer price for NWR to A$0.066/0.067 per share on July 17, and CAML had until July 24 to match this offer. As a result of CAML’s decision, the NWR board has withdrawn its prior recommendation for CAML and now supports Kinterra’s bid. The termination of the deal will result in a break fee of A$2.4 million (US$1.56 million) payable to CAML. The company also holds a 12% stake in NWR, valued at approximately $19 million. CAML’s decision demonstrates restraint from the board, as the company was reportedly reaching its upper limit on pricing at Kinterra’s previous bid price of A$0.063/0.064 per share. Matching or exceeding Kinterra’s latest offer would have likely required alternative financing or increased leverage, especially considering the private equity fund’s access to $850 million in undrawn capital commitments. While this development puts CAML back at square one regarding portfolio growth initiatives, the company continues to offer exposure to copper, which represents 58% of its projected 2025 revenue. CAML is forecast to generate a free cash flow yield of 16% and dividend yield of 12% over the next three years. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Central Asia Metals walks away from New World Resources acquisition
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...